What Lumira Ventures does

Lumira Ventures, legally Lumira Capital Investment Management Inc., is a Toronto-headquartered life sciences venture capital firm that invests in biotechnology and medical technology companies across North America. Founded in 1989, the firm partners with mission-driven entrepreneurs building companies that develop and commercialize healthcare products, with stated emphasis on underserved markets beyond traditional venture hubs. The firm operates from four offices — Toronto (headquarters at 141 Adelaide Street, Suite 770), Montreal (Espace CDPQ), Vancouver, and Boston (177 Huntington Ave., 17th Floor) — providing direct coverage of Canada's three largest biotech clusters plus a US anchor.

The firm's principal offering is its series of venture funds. Fund V, announced April 2026, targets a final close of $200 million with an initial close that included a $52 million Series B financing for a pre-commercial-stage medical device company. Earlier vehicles include the Angelini Lumira Biosciences Fund and other co-investment structures that back companies from Series A through growth stages. Investment activity is concentrated in therapeutic areas including oncology (Alpha-9 Oncology $175M Series C, KisoJi Biotechnology, Axonis Therapeutics $115M Series A), cardiology (Corvia Medical, Cardiac Dimensions $53M Series E), metabolic disease (COUR Pharmaceuticals, Congruence Therapeutics), neurology (Cadence Neuroscience, XyloCor Therapeutics), and adjacent medtech adjacencies such as peripheral nerve stimulation (Nervonik), reversible contraception (Contraline), and histotripsy platforms (HistoSonics, Sound Blade Medical). Portfolio companies are frequently co-invested alongside strategic partners including Roche Venture Fund, Sanofi, J&J Innovation-JJDC, Jeito Capital, and Amzak Health.

Lumira Ventures generates revenue through two mechanisms typical of venture capital fund managers: recurring management fees on committed fund capital and carried interest on profits realized from successful portfolio exits. The firm has achieved over $8 billion in exits since 2024, including the $2.25 billion acquisition of HistoSonics by a consortium of investors in August 2025 (followed by a $3.75 billion valuation in a June 2026 financing round), Royal Philips' acquisition of SpectraWAVE, and AstraZeneca's acquisition of Fusion Pharmaceuticals. In 2026, the Canadian Venture Capital and Private Equity Association recognized Lumira with the VC Global Dealmaker of the Year Award, and the firm announced the Cancer Breakthrough Fund in partnership with the Terry Fox Foundation and the Canadian Cancer Society as a thematic extension of its platform. Co-founder Gerry Brunk is Managing Partner alongside co-founder Peter van der Velden.

Name

Lumira Ventures

Legal name

Lumira Capital Investment Management Inc.

Website

https://lumiraventures.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

11–50 employees

Short description

Lumira Ventures is a Canadian life sciences venture capital firm investing in biotechnology and medical technology companies across North America. The firm manages Fund V targeting $200M and has achieved over $8 billion in portfolio exits since 2024.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital Management

NAICS

Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Other Financial Vehicles (525990)

SIC

Investment Advice (6282), Investors, Nec (6799)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Venture capital investing
• Life sciences funding
• Biotechnology investments
• Medical technology venture
• Healthcare equity capital

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Venture Capital Fund Management: Lumira Ventures generates returns through management fees on committed capital and carried interest (performance fees) on fund profits from successful exits of portfolio companies. The firm has achieved over $8 billion in exits since 2024, including notable exits such as HistoSonics' $2.25 billion acquisition by a consortium of investors and SpectraWAVE's acquisition by Royal Philips.

Distribution channels1 record

Marketing channels3 records

Core offering

Lumira Ventures is a North American life sciences venture capital firm that raises dedicated healthcare-focused funds from institutional limited partners and invests the capital into biotechnology and medical technology companies across North America. The firm partners with mission-driven entrepreneurs to build transformative life sciences companies focused on developing and commercializing impactful products for patients. Returns are generated through management fees on committed capital and carried interest on successful portfolio exits.

Product overview

Lumira Ventures is a leading North American life sciences venture capital firm that invests in transformative biotechnology and medical technology companies. The firm operates as a single unified investment platform with Fund V as its primary offering — a $200 million healthcare-focused venture fund targeting biotechnology and medical technology companies across North America, with emphasis on underserved markets beyond traditional venture hubs. The firm also manages earlier funds and co-investment vehicles, collectively backing portfolio companies throughout their development lifecycle from Series A through growth stages.

Differentiator

Problem solved

Functional benefit

Products and services

• Lumira Ventures Fund V A $200 million healthcare-focused venture fund that targets biotechnology and medical technology companies across North America, with emphasis on underserved markets beyond traditional venture hubs. The fund provides venture capital financing to mission-driven entrepreneurs developing and commercializing impactful products for patients, and is offered to qualified institutional limited partners through private placement.

Quantifiable outcome

• Over $8 billion in exits achieved since 2024
• +3 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Amplitude Ventures: Canadian healthcare and life sciences venture capital firm with offices in Montreal and Toronto. Amplitude is the most direct peer given overlapping Canadian geography, healthcare-only thesis, and participation in rounds such as Congruence Therapeutics where Lumira also invested.
• Amzak Health: U.S. healthcare-focused venture and growth firm that has co-led multiple rounds with Lumira (Sound Blade Medical Series A, Nervonik Series B). Closely comparable in stage, sector focus, and check size, with a consistent co-investment relationship.
• Teralys Capital: One of Canada's largest venture capital fund-of-funds and direct investors, with significant life sciences exposure. Operates in the same Canadian institutional-investor ecosystem and competes for healthcare deal flow.
• BDC Capital (Thrive Venture Fund): Canadian development bank investment arm with an active life sciences fund that has co-invested alongside Lumira (Congruence Therapeutics). Direct Canadian healthcare VC peer.

Broad incumbents

• OrbiMed: One of the world's largest healthcare-dedicated investment firms, with private equity, venture, and public equity strategies. Has co-invested with Lumira in Congruence Therapeutics; competes at the larger end of the same deal set.
• Versant Ventures: Established healthcare-focused venture firm with multi-stage strategies across biotech, medtech, and healthcare services. Comparable in sector focus but materially larger in AUM and check size.
• ARCH Venture Partners: Premier U.S. life sciences venture firm founded in 1986. Targets transformative biotech and medtech platforms globally — comparable thesis to Lumira but at materially larger fund sizes.
• Atlas Venture: Boston-based early-stage biotech venture firm. Directly comparable in therapeutic-area focus and stage orientation; serves as a benchmark for biotech-specialist platforms.
• Vivo Capital: Healthcare-focused investment firm operating across venture, growth, and public equities. Sector-specialist comparable with broader geographic and strategy breadth.

Emerging players

• Andreessen Horowitz (a16z Bio): Large multi-stage venture firm with a dedicated bio/health fund. Increasingly active in healthcare VC at scale; represents an emerging competitive force for sector-focused investors like Lumira.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lumira-ventures
• Xx.com/LumiraVentures

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments114 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lumira Ventures